Compositions and methods for treating tissue ischemia

• US 20060194776A1
• Filed: 12/28/2005
• Published: 08/31/2006
• Est. Priority Date: 06/30/2003
• Status: Abandoned Application

• Current Assignee: AnorMED, Inc. (Sanofi ), Steward Research And Specialty Projects Corporation
• Original Assignee: Caritas St Elizabeth's Medical Center of Boston Incorporated (Caritas St. Elizabeth's Medical Center)
• Inventors: Isner, Linda, Bridger, Gary J., Losordo, Douglas W., Isner, Jeffrey M.
• Application Number:
  US11/321,143
• Publication Number:
  US 20060194776A1
• Time in Patent Office: Days
• US Class Current: 514/183
• CPC Class Codes: A61K 31/275 Nitriles; Isonitriles
• CPC Class Codes: A61K 31/33 Heterocyclic compounds
• CPC Class Codes: A61K 31/38 having sulfur as a ring hetero atom
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465

Abstract

The present invention generally provides methods for preventing or treating tissue ischemia using CXCR4 antagonists. In one embodiment, the methods include administering to a mammal a therapeutically effective amount of a particular bicylic polyamine to elevate peripheral blood EPCs. The invention has a wide spectrum of applications including reducing or eliminating tissue ishemica associated with a myocardial infarct (heart attack).

Claims

1. A method of treating tissue ischemia comprising administering to a subject a therapeutically effective amount of a CXCR4 antagonist, wherein the CXCR antagonist elevates the peripheral blood endothelial progenitor cell (EPC) count of the subject, thereby treating the tissue ischemia in the subject.

2. The method of claim 1, further comprising administering a therapeutically effective amount of an agent that promotes EPC proliferation to the subject.

3. The method of claim 2, wherein the agent that promotes EPC proliferation is administered to the subject prior to the administration of the CXCR4 antagonist.

4. The method of claim 2, wherein the agent that promotes EPC proliferation is SDF-1.

5. The method of claim 2, wherein the agent that promotes EPC proliferation is selected from the group consisting of GRO-β

, a Flt-3 ligand, a glutathione S-transferase inhibitor, angiotensin or an analog thereof, a CD26 inhibitor, a VLA4 inhibitor, and a kit ligand.

6. The method of any of claims 1-5, further comprising administering a therapeutically effective amount of an inhibitor of vascular endothelial growth factor-mediated vascular permeability to the subject.

7. The method of any of claims 1-6, further comprising:

a) removing EPCs from the subject,

b) contacting the EPCs with a therapeutically effective amount of an agent that promotes EPC proliferation, and

c) returning the EPCs to the subject.

8. The method of any of claims 1-7, wherein the subject has had or is having an acute myocardial infarction.

9. The method of claim 8, wherein the CXCR4 antagonist is administered to the subject less about 12 hours or less after suffering from an acute myocardial infarction.

10. The method of any of claims 1-9, wherein the subject is suffering from or at risk for developing restenosis.

11. The method of any of claims 1-10, wherein the subject has suffered or is suffering from a disorder or condition selected from the group consisting of arteriosclerosis, stroke, chronic ischemia of myocardium, chronic ischemia of lower extremities, and organ regeneration in mycoardium, limbs, brain, or liver.

12. The method of any of claims 1-11, wherein the CXCR4 antagonist is administered to the subject by an intravenous or subcutaneous route.

13. The method of any of claims 1-12, wherein the CXCR4 antagonist is administered to the subject in the dosage range of about 0.1 μ

g/kg-5 mg/kg of body weight.

14. The method of any of claims 1-13, wherein the CXCR4 antagonist is administered to the subject in a single dose or by continuous infusion.

15. The method of any of claims 1-14, wherein the CXCR4 antagonist has the formula:

Z-linker-Z′

or a pharmaceutically acceptable salt thereof

wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system;

wherein Z′

may be embodied in a form as defined by Z above, or alternatively may be of the formula

—

N(R)—

(CR₂)_n—

X 

 

(1)

wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; and

wherin “

linker”

represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

16. The method of claim 15, wherein Z and Z′

are both cyclic polyamines.

17. The method of any of claims 15-16, wherein Z and Z′

are identical.

18. The method of any of claims 15-16, wherein Z contains 12-24 members and contains 4 nitrogen atoms.

19. The method of any of claims 15-18, wherein Z and Z′

are both 1,4,8,11-tetraazocyclotetradecane.

20. The method of any of claims 15-19, wherein the linker comprises an aromatic ring bracketed by two methylene moieties.

21. The method of any of claims 15-20, wherein the linker is 1,4-phenylene-bis-methylene.

22. The method of any of claims 1-21, wherein the CXCR4 antagonist is 1,1′

-1,4-phenylene-bis-(methylene)-bis-1,4,8,11-tetraazacyclotetradecane (AMD-3100).

23. The method of claim 15, wherein the CXCR4 antagonist is selected from the group consisting of:

N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-aminomethyl)pyridine;

7,7′

-[1,4-phenylenebis(methylene)]bis-4,7,10,17-tetraazabicyclo-[13.3.1]heptadeca-1(17),13,15-triene;

7,7′

-[1,4-phenylenebis(methylene)]bis-3,7,11,17-tetraazabicyclo[13.3.1]heptadeca-1(17),13,15-triene;

1,1′

-[1,3-phenylenebis(methylene)]-bis-1,4,8,11-tetra-azacyclotetradecane;

1,1′

-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetra-azacyclotetradecane;

1,1′

-[1,4-phenylene-bis-(methylene)]-bis-1,4,7,10-tetraazacyclotetradecane;

1,1′

-[1,3-phenylene-bis-(methylene)]-bis-1,4,7,10-tetraazacyclotetradecane;

11,11′

-(1,2-propanediyl)bis-1,4,8,11-tetraazacyclotetradecane;

N-[4-(1,4,7-triazacyclotetra-decane)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine;

N-[7-(4,7,10-triazabicyclo[13.3.1]heptadeca-[(17),13,15-triene)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine;

N-[7-(4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-1 (17),13,15-triene)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine; and

N-[4-[4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-1 (17),13,15-triene]-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine.

24. The method of any of claims 15-23, wherein formula (1) is in the form of a pharmaceutically acceptable salt.

25. The method of claim 24, wherein the pharmaceutically acceptable salt is an acid addition salt.